Characteristic | EXP3B (n=28) |
EXP4–5 (n=111) |
---|---|---|
Prior therapy for NSCLC | 1 prior 2nd-generation ALK TKI ± CT |
≥2 prior ALK TKIsd ± CT |
Age, years | ||
Median (IQR) | 54.0 (46.5-64.0) | 51.0 (43.0-59.0) |
Mean (SD) | 55.0 (11.6) | 51.9 (11.5) |
Range | 33-77 | 29-83 |
Sex | ||
Female | 16 (57%) | 62 (56%) |
Male | 12 (43%) | 49 (44%) |
Race | ||
White | 7 (25%) | 59 (53%) |
Black | 1 (4%) | 0 |
Asian | 16 (57%) | 37 (33%) |
Other | 1 (4%) | 5 (5%) |
Unspecifiede | 3 (11%) | 10 (9%) |
ECOG PS | ||
0 | 15 (54%) | 46 (41%) |
1 | 13 (46%) | 59 (53%) |
2 | 0 | 6 (5%) |
Brain metastases | ||
Present at baselinef | 13 (46%) | 83 (75%) |
Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics.
The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.
I confirm that I am a healthcare professional* resident in the Republic of Ireland.
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses
Terms of use
PP-UNP-IRL-0784. June 2024